Cagrilintide Research Hub — Amylin Analog & Satiety Studies
Cagrilintide is a long-acting analog of amylin investigated in satiety, gastric-emptying and metabolic-research models, often studied in combination with GLP-1 agonists.
What this hub covers
- Amylin receptor (AMY-R) agonism
- Satiety and gastric-emptying literature
- Combination studies with semaglutide (CagriSema)
- Body-composition endpoints
- Reconstitution and storage
Cagrilintide research articles
All research →Tirzepatide vs Cagrilintide — Research Comparison (2026)
Tirzepatide vs cagrilintide compared: dual GIP/GLP-1 incretin vs long-acting amylin analog, mechanism, dosing and stacking research.
Read article →Cagrilintide Benefits and Side Effects: A Research Guide
Research guide on Cagrilintide: long-acting amylin analog mechanism, satiety and gastric-emptying literature, CagriSema combination research, and the documented side-effect profile.
Read article →Semaglutide Benefits and Side Effects: A Research Guide
Published benefits, side effects, and cardiovascular-outcomes evidence for semaglutide — the most extensively characterised GLP-1 receptor agonist in the modern incretin literature.
Read article →Cagrilintide vs Semaglutide: Amylin vs GLP-1 Research
Compare cagrilintide (long-acting amylin analog) and semaglutide (GLP-1 agonist) — mechanism, half-life, satiety pathways, and the rationale for combination research.
Read article →Semaglutide vs Tirzepatide: Research Comparison
Side-by-side comparison of semaglutide and tirzepatide receptor activity, half-life, and metabolic research findings.
Read article →Cagrilintide Dosing & Protocols — Research Reference
Reference dose tiers, titration ladder, reconstitution math, and semaglutide co-administration scheduling from the published cagrilintide (amylin analogue) research record.
Read article →Cagrilintide research FAQ
- What is Cagrilintide?
- Cagrilintide is a long-acting synthetic analog of the pancreatic hormone amylin, studied as an amylin-receptor agonist in metabolic research.
- Why is it studied alongside semaglutide?
- Combined amylin + GLP-1 agonism (CagriSema) is investigated in the published literature for additive/synergistic effects on satiety, gastric emptying and body composition.
All content on this hub is provided strictly for laboratory research purposes. Compounds listed are not for human or veterinary consumption. See our research-use disclosure for full terms.